Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19

View ORCID ProfileCarolyn T. Bramante, Christopher J. Tignanelli, Nirjhar Dutta, Emma Jones, Leonardo Tamaritz, Jeanne Clark, Genevieve Melton-Meaux, Michael Usher, Sayeed Ikramuddin
doi: https://doi.org/10.1101/2020.09.01.20185850
Carolyn T. Bramante
1Department of Medicine, University of Minnesota, Division of General Internal Medicine, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Carolyn T. Bramante
  • For correspondence: bramante@umn.edu
Christopher J. Tignanelli
2Department of Surgery, University of Minnesota Division of Surgical Oncology, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nirjhar Dutta
1Department of Medicine, University of Minnesota, Division of General Internal Medicine, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Jones
2Department of Surgery, University of Minnesota Division of Surgical Oncology, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonardo Tamaritz
3University of Miami, Division of Cardiology and Miami VA Healthcare administration, Miami, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeanne Clark
4Department of Medicine, Johns Hopkins School of Medicine, Division of General Internal Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Genevieve Melton-Meaux
2Department of Surgery, University of Minnesota Division of Surgical Oncology, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Usher
1Department of Medicine, University of Minnesota, Division of General Internal Medicine, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sayeed Ikramuddin
2Department of Surgery, University of Minnesota Division of Surgical Oncology, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Covid-19 disease causes significant morbidity and mortality through increase inflammation and thrombosis. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis are states of chronic inflammation and indicate advanced metabolic disease. We sought to understand the risk of hospitalization for Covid-19 associated with NAFLD/NASH.

Methods Retrospective analysis of electronic medical record data of 6,700 adults with a positive SARS-CoV-2 PCR from March 1, 2020 to Aug 25, 2020. Logistic regression and competing risk were used to assess odds of being hospitalized. Additional adjustment was added to assess risk of hospitalization among patients with a prescription for metformin use within the 3 months prior to the SARS-CoV-2 PCR result, history of home glucagon-like-peptide 1 receptor agonist (GLP-1 RA) use, and history of metabolic and bariatric surgery (MBS). Interactions were assessed by gender and race.

Results A history of NAFLD/NASH was associated with increased odds of admission for Covid-19: logistic regression OR 2.04 (1.55, 2.96, p<0.01), competing risks OR 1.43 (1.09-1.88, p<0.01); and each additional year of having NAFLD/NASH was associated with a significant increased risk of being hospitalized for Covid-19, OR 1.86 (1.43-2.42, p<0.01). After controlling for NAFLD/NASH, persons with obesity had decreased odds of hospitalization for Covid-19, OR 0.41 (0.34-0.49, p<0.01). NAFLD/NASH increased risk of hospitalization in men and women, and in all racial/ethnic subgroups. Mediation treatments for metabolic syndrome were associated with non-significant reduced risk of admission: OR 0.42 (0.18-1.01, p=0.05) for home metformin use and OR 0.40 (0.14-1.17, p=0.10) for home GLP-1RA use. MBS was associated with a significant decreased risk of admission: OR 0.22 (0.05-0.98, p<0.05).

Conclusions NAFLD/NASH is a significant risk factor for hospitalization for Covid-19, and appears to account for risk attributed to obesity. Treatments for metabolic disease mitigated risks from NAFLD/NASH. More research is needed to confirm risk associated with visceral adiposity, and patients should be screened for and informed of treatments for metabolic syndrome.

Question Does NAFLD/NASH independently increase risk for poor outcomes from Covid-19?

Findings In this observational study, a history of NAFLD/NASH was associated with a significantly increased odds of hospitalization. Metabolic surgery was protective against admission in persons with NAFLD/NASH and Covid-19. Metformin and glucagon like peptide 1 receptor agonists were associated with non-significant protecting against admission.

Meaning Treatment for metabolic syndrome greatly reduce the elevated risk of hospitalization for Covid-19 among persons with NAFLD/NASH.

Competing Interest Statement

Disclosures: Dr. Tignanelli is PI on randomized trials for Covid-19, but not related to metformin. Dr. Bramante has submitted an IND for a prospective trial for metformin.

Funding Statement

1.This research was supported by the Agency for Healthcare Research and Quality (AHRQ) and Patient-Centered Outcomes Research Institute (PCORI), grant K12HS026379 (CJT) 2.This research was supported by the National Center for Advancing Translational Sciences, grants KL2TR002492 and UL1TR002494 (CTB) 3.This research was supported by COVID-19 Rapid response grant UM 2020-2231 4.This research was supposed by the Minnesota Learning Health System Mentored Training Program (MH-LHS), M Health Fairview Institutional Funds (CTB).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The University of MN IRB approved this study, STUDY00001489

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data is available in the M Health Fairview Data Cloud

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted September 02, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19
Carolyn T. Bramante, Christopher J. Tignanelli, Nirjhar Dutta, Emma Jones, Leonardo Tamaritz, Jeanne Clark, Genevieve Melton-Meaux, Michael Usher, Sayeed Ikramuddin
medRxiv 2020.09.01.20185850; doi: https://doi.org/10.1101/2020.09.01.20185850
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19
Carolyn T. Bramante, Christopher J. Tignanelli, Nirjhar Dutta, Emma Jones, Leonardo Tamaritz, Jeanne Clark, Genevieve Melton-Meaux, Michael Usher, Sayeed Ikramuddin
medRxiv 2020.09.01.20185850; doi: https://doi.org/10.1101/2020.09.01.20185850

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Gastroenterology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5219)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5823)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (94)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1994)
  • Radiology and Imaging (345)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)